trial

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

NCTId NCT02420015
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 35 (actual)
Sponsored by Duke University
Primary completion 2019-01-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
35 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2017-03-27
Primary completion
2019-01-24
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Nicotine replacement therapyBupropioncognitive-behavioral smoking cessation counselingMobile Contingency ManagementStay Quit CoachSMS text messaging

Sponsors

Duke UniversityLead Sponsor

Investigators

1
Jean M. Addington, Ph.D.Principal Investigator

Sites

1 total
Durham, United States

Facts & assertions

4 sourced
Enrollment
35
Phase
PHASE4
Primary Completion Date
2019-01-24
Status
COMPLETED
relationships
The graph out of here
drug
Nicotine replacement therapy
drug
Bupropion
drug
cognitive-behavioral smoking cessation counseling
drug
Mobile Contingency Management
drug
Stay Quit Coach
drug
SMS text messaging
drug
lead_sponsor
Duke University
company
indication
Cigarette Smoking
indication
Schizophrenia
indication
Cigarette Smoking
indication
investigator
Jean M. Addington, Ph.D.
person